Radioimmunotherapy with alpha-emitting nuclides

[1]  D. Kocher.  Radioactive Decay Data Tables: A Handbook of Decay Data for Application to Radiation Dosimetry and Radiological Assessments , 1981 .

[2]  R. McLendon,et al.  Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. , 1994, Cancer research.

[3]  J. Zweit,et al.  Radionuclides and carrier molecules for therapy. , 1996, Physics in medicine and biology.

[4]  S. Goddu,et al.  Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M. Brechbiel,et al.  An effective chelating agent for labelling of monoclonal antibody with 212Bi for α-particle mediated radioimmunotherapy , 1991 .

[6]  D. Scheinberg,et al.  Alpha particle emitting constructs of recomblnant humanized antl-CD33 for myelold teukemlas , 1994 .

[7]  J. Humm.  A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. , 1987, International journal of radiation oncology, biology, physics.

[8]  D. Scheinberg,et al.  Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. , 1982, Cancer research.

[9]  J. Humm,et al.  A model of cell inactivation by alpha-particle internal emitters. , 1993, Radiation research.

[10]  D. Bigner,et al.  Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. , 1996, Acta oncologica.

[11]  L. Mausner,et al.  In vivo generator for radioimmunotherapy , 1989 .

[12]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[13]  R. E. Schenter,et al.  Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. , 1997, Radiation research.

[14]  N. Blagojevic,et al.  Alpha‐ and beta‐emitting radiolanthanides in targeted cancer therapy: The potential role of terbium‐149 , 1996, Nuclear medicine communications.

[15]  D. Scheinberg,et al.  Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. , 1982, Science.

[16]  D. Scheinberg,et al.  Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. , 1989, Leukemia.

[17]  A. Harrison,et al.  Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. , 1987, NCI monographs : a publication of the National Cancer Institute.

[18]  W. Inkret,et al.  Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. , 1991, Radiation research.

[19]  D. Bigner,et al.  Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates , 1996 .

[20]  J C Roeske,et al.  Dosimetric framework for therapeutic alpha-particle emitters. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J C Roeske,et al.  Analytic microdosimetry for radioimmunotherapeutic alpha emitters. , 1992, Medical physics.

[22]  L. T. Dillman,et al.  MIRD : radionuclide data and decay schemes , 1989 .

[23]  R Offord,et al.  The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice. The ISOLDE Collaboration. , 1997, Nuclear medicine and biology.

[24]  J. Humm,et al.  A Monte-Carlo approach to the microdosimetry of 224Ra in murine compact and cancellous bone. , 1988, Health physics.

[25]  Herbert Malamud,et al.  MIRD Primer for Absorbed Dose Calculations , 1989 .

[26]  M. Brechbiel,et al.  Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter , 1992 .

[27]  M. Zalutsky,et al.  Targeted therapy using alpha emitters. , 1996, Physics in medicine and biology.

[28]  D. Scheinberg,et al.  Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. , 1983, Cancer research.

[29]  V. L. Alvarez,et al.  Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody. , 1990, Cancer research.

[30]  D. Fisher,et al.  The microdosimetry of lymphocytes irradiated by alpha-particles. , 1982, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[31]  G T Chen,et al.  Microdosimetric concepts in radioimmunotherapy. , 1993, Medical physics.

[32]  Two Approaches for Enhancing Radioimmunotherapy: ∝ Emitters and Hyperthermia , 1996 .

[33]  B. Spivakov,et al.  Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions , 1979 .

[34]  Y. Erdi,et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  C. Coleman,et al.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates. , 1988, Science.

[36]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[37]  M. Brechbiel,et al.  212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. , 1988, Journal of the National Cancer Institute.

[38]  S. Larson,et al.  Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. , 1995, Cancer research.

[39]  J. Humm,et al.  Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. , 1992, Radiation research.

[40]  G. Sgouros,et al.  Dosimetry of radium-223 and progeny , 1999 .

[41]  D. Scheinberg,et al.  A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. , 1995, Nuclear medicine and biology.

[42]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .

[43]  W. Inkret,et al.  Radiobiology of α Particles: III. Cell Inactivation by α-Particle Traversals of the Cell Nucleus , 1991 .

[44]  D. Bigner,et al.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Waldmann,et al.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. McLendon,et al.  Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate , 1994 .

[47]  E. M. Link,et al.  211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases. , 1990, Cancer research.

[48]  D. Scheinberg,et al.  Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. , 1992, Cancer research.